☆ 4.6 Review

Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events

CLINICAL KIDNEY JOURNAL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Transplantation

AA amyloidosis associated with cancers

Joyita Bharati et al.

Summary: Systemic AA amyloidosis is associated with autoimmune disorders, chronic infections, and malignant tumors such as renal cell carcinoma. Lung cancer and basal cell carcinoma skin are also often reported with AA amyloidosis. The immune response from the tumor or immune therapy may contribute to the association between cancer and AA amyloidosis. Treatment involves targeting the underlying malignancy or discontinuing the offending agent.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

添加到收藏夹

Review Urology & Nephrology

Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy

Nupur N. Uppal et al.

Summary: Novel immunotherapy drugs have revolutionized cancer medicine, but they can also lead to immune-related adverse events, including electrolyte disorders. This review examines the associated electrolyte disorders, such as hyponatremia, hypokalemia, hypercalcemia, hypocalcemia, and hyperphosphatemia. Early recognition and prompt diagnosis are crucial for managing these novel electrolyte disorders.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

添加到收藏夹

Review Transplantation

Immune checkpoint inhibitor-associated hypercalcaemia

Hassan Izzedine et al.

Summary: Immune checkpoint inhibitors (CPIs) are important for treating advanced cancers, but they can also cause immune-related adverse events (irAEs), including hypercalcemia. The causes of CPI-induced hypercalcemia may include endocrine diseases, granulomas, hormonal imbalances, and disease progression. Early recognition and treatment of hypercalcemia are crucial for patient outcomes.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

Sophia Bylsma et al.

Summary: Immune checkpoint inhibitors (ICIs) have become crucial in the treatment of many cancer types, but they also bring about a new form of drug toxicity called immune-related adverse events (irAEs). irAEs are common and can have serious consequences, leading to treatment discontinuation and adverse outcomes for patients. However, with careful consideration and appropriate patient selection, resuming treatment with ICIs can be a reasonable approach.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

添加到收藏夹

Letter Urology & Nephrology

Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

Shruti Gupta et al.

KIDNEY INTERNATIONAL (2022)

添加到收藏夹

Article Oncology

Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study

Robert P. Carroll et al.

Summary: Maintaining baseline immunosuppression before treatment with an immune checkpoint inhibitor in kidney transplant recipients might not affect expected efficacy and might reduce the risk of allograft rejection mediated by immune checkpoint inhibitors.

LANCET ONCOLOGY (2022)

添加到收藏夹

Editorial Material Urology & Nephrology

Acute Interstitial Nephritis on Positron-Emission Tomography-Computed Tomography Imaging

Jing Miao et al.

KIDNEY MEDICINE (2022)

添加到收藏夹

Article Urology & Nephrology

Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience

Diana Oleas et al.

Summary: This study highlights the occurrence of AIN in patients with solid organ metastatic malignancies treated with CPIs, with the kidney being a commonly affected organ. The majority of patients showed improvement in kidney function with steroid treatment, indicating a favorable response to this type of toxicity.

CLINICAL KIDNEY JOURNAL (2021)

添加到收藏夹

Article Oncology

Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity

Jonathan D. Sorah et al.

Summary: This study investigated the incidence and predictive factors of immune-related acute kidney injury (irAKI) caused by ICIs. It found that a history of autoimmune disease and other immune-related adverse events (irAEs) were associated with irAKI, highlighting the importance of early recognition and steroid administration for a positive outcome.

JOURNAL OF IMMUNOTHERAPY (2021)

添加到收藏夹

Review Urology & Nephrology

A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease

Abhijat Kitchlu et al.

Summary: This study summarized the association between immune checkpoint inhibitors and glomerular diseases, revealing various forms of diseases including pauci-immune glomerulonephritis, podocytopathies, and C3GN. Most patients experienced complete or partial recovery from acute kidney injury, but a portion of patients still required dialysis.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Urology & Nephrology

A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant

Naoka Murakami et al.

Summary: Immune checkpoint inhibitors pose a high risk of acute rejection in kidney transplant patients but may lead to improved cancer outcomes. Prospective studies are needed to determine optimal immunosuppression strategies to improve patient outcomes.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Oncology

Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors

Harish Seethapathy et al.

Summary: This study investigated the impact of immune checkpoint inhibitors on kidney function in patients with renal cell carcinoma and urothelial carcinoma. The results showed that acute kidney injury and sustained eGFR loss were common, and immune-related adverse events may be a novel risk factor for kidney function decline in patients receiving ICIs.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Transplantation

Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors

Harish Seethapathy et al.

Summary: Hyponatremia is common in cancer patients receiving ICIs, but endocrinopathies are not a common cause of severe hyponatremia. Other severe electrolyte abnormalities are also commonly observed.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Letter Urology & Nephrology

Immune checkpoint inhibitor-associated electrolyte disorders: query of the Food and Drug Administration Adverse Event Reporting System

Rimda Wanchoo et al.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Review Urology & Nephrology

KDIGO 2021 CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF GLOMERULAR DISEASES

Brad H. Rovin et al.

Summary: The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases aims to assist clinicians caring for individuals with glomerular disease by providing actionable recommendations and valuable infographics. It also proposes research recommendations for areas where there are gaps in knowledge, targeting a broad audience of clinicians treating glomerular disease. The guideline development process followed an explicit evidence review and the treatment approaches are based on systematic reviews, evidence synthesis, and the GRADE approach.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Urology & Nephrology

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events

Busra Isik et al.

Summary: This study found that at the time of AKI, ICI-AKI patients had significantly higher SCr, CRP, and uRBP/Cr levels compared to non-ICI-AKI patients. The time from ICI initiation to AKI was shorter in the ICI-AKI group compared to the referent group. Among the ICI-AKI group, 39% of patients achieved complete renal recovery within 3 months.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Oncology

Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study

M. Espi et al.

Summary: A retrospective analysis of patients undergoing checkpoint inhibitor therapy revealed a 3.7% incidence of CPI-induced AKI, primarily acute tubulointerstitial nephritis with mild severity. Despite a higher occurrence of other IRAEs in these patients, it was not associated with an increased risk of AKI.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Acute kidney injury in patients treated with immune checkpoint inhibitors

Shruti Gupta et al.

Summary: Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) is an important toxicity among cancer patients. Impaired renal function at baseline, PPI use, and extrarenal irAEs were associated with a higher risk of ICPi-AKI. Two-thirds of patients experienced renal recovery following ICPi-AKI, with corticosteroid treatment associated with improved recovery.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study

Meghan D. Lee et al.

Summary: Treatment with a rapid corticosteroid taper in patients with ICI-induced nephritis leads to excellent kidney outcomes, but there was no significant difference in time to renal recovery between the rapid-taper group and the standard-of-care group.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Ahmad A. Tarhini et al.

Summary: The impact of immune-related adverse events (irAEs) on the use of immunotherapy and their management on relapse-free survival (RFS) and overall survival (OS) outcomes is not well understood. Patients experiencing grades 1-2 irAEs had better RFS and OS outcomes compared to those with no AE, with rash and endocrine irAEs being the most significant factors. Higher grade irAEs had less benefits, and use of corticosteroids and immunosuppressants did not significantly affect RFS or OS outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Urology & Nephrology

Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review

Abhijat Kitchlu et al.

Summary: ICI therapy has substantially improved prognosis of patients with advanced malignancy, with similar incidence of immune-related adverse events in ESKD patients compared with the general population. Severe reactions have been seen in some cases, but cancer remission was observed in close to 30% of patients. More data from prospective studies are needed to assess outcomes more accurately.

CLINICAL KIDNEY JOURNAL (2021)

添加到收藏夹

Article Oncology

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer et al.

Summary: ICIs are standard treatments for cancer, but come with risks of immune-related adverse events. The SITC convened an expert panel to develop guidelines for managing irAEs, aiming to improve patient outcomes through evidence-based recommendations.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis

Kang Liu et al.

Summary: The study analyzed 95 eligible randomized controlled trials involving 40,552 participants and found that both ICI-based regimens and traditional cancer therapies had a higher risk of RAEs and AKI compared to placebo. Among the various ICI therapies, anti-CTLA-4 appeared to be associated with increased toxicity, while anti-PD-1 was safer.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Editorial Material Urology & Nephrology

A new expression of immune checkpoint inhibitors' renal toxicity: when distal tubular acidosis precedes creatinine elevation

Xavier Charmetant et al.

CLINICAL KIDNEY JOURNAL (2020)

添加到收藏夹

Review Urology & Nephrology

Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?

Mark A. Perazella et al.

KIDNEY INTERNATIONAL (2020)

添加到收藏夹

Article Urology & Nephrology

Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study

Frank B. Cortazar et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Acute hyponatremia from immune checkpoint inhibitor therapy for non-small cell lung cancer

Sai Prasad Desikan et al.

POSTGRADUATE MEDICAL JOURNAL (2020)

添加到收藏夹

Article Urology & Nephrology

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series

Ian A. Strohbehn et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2020)

添加到收藏夹

Article Oncology

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

Lihong Peng et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

添加到收藏夹

Review Cell Biology

Immune checkpoint signaling and cancer immunotherapy

Xing He et al.

CELL RESEARCH (2020)

添加到收藏夹

Review Oncology

Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis

Luca Cantini et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)

添加到收藏夹

Article Oncology

Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes

Alejandro Meraz-Munoz et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Urology & Nephrology

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events

Sandra M. Herrmann et al.

KIDNEY INTERNATIONAL REPORTS (2020)

添加到收藏夹

Review Urology & Nephrology

Hyponatremia in the cancer patient

Biruh T. Workeneh et al.

KIDNEY INTERNATIONAL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A decade of immune-checkpoint inhibitors in cancer therapy

Caroline Robert

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Review Immunology

The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Rossana Franzin et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice

Ming-Chun Kuo et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Urology & Nephrology

Renal Tubular Acidosis and Immune Checkpoint Inhibitor Therapy: An Immune-Related Adverse Event of PD-1 Inhibitor-A Report of 3 Cases

Sandra M. Herrmann et al.

KIDNEY MEDICINE (2020)

添加到收藏夹

Article Oncology

Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma

Viral Patel et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Urology & Nephrology

Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy Single Center Experience of Management and Drug Rechallenge

Sandhya Manohar et al.

KIDNEY360 (2020)

添加到收藏夹

Article Transplantation

Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis

Sandhya Manohar et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)

添加到收藏夹

Article Oncology

Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study

Abhijat Kitchlu et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

Maddalena Centanni et al.

CLINICAL PHARMACOKINETICS (2019)

添加到收藏夹

Review Medicine, General & Internal

Immune checkpoint inhibitor-induced colitis: A comprehensive review

Aniruddh Som et al.

WORLD JOURNAL OF CLINICAL CASES (2019)

添加到收藏夹

Article Oncology

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors

Alberto Pavana et al.

ONCOLOGIST (2019)

添加到收藏夹

Article Oncology

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

Fiamma Berner et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

Noha Abdel-Wahab et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Immunology

Urine macrophages reflect kidney macrophage content during acute tubular interstitial and glomerular injury

Ping-ping Sun et al.

CLINICAL IMMUNOLOGY (2019)

添加到收藏夹

Article Oncology

C-reactive protein as an early marker of immune-related adverse events

Amir-Reza Abolhassani et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Urology & Nephrology

The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors

Harish Seethapathy et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab

Yeonghee Eun et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Article Oncology

Immune dysregulation in cancer patients developing immune-related adverse events

Shaheen Khan et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

Omar Mamlouk et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis

David Qualls et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Urology & Nephrology

Renal toxicities associated with pembrolizumab

Hassan Izzedine et al.

CLINICAL KIDNEY JOURNAL (2019)

添加到收藏夹

Article Oncology

Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies

Yoshiyuki Nakamura et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Urology & Nephrology

Anti - PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1

Clarissa Cassol et al.

KIDNEY INTERNATIONAL REPORTS (2019)

添加到收藏夹

Article Oncology

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

Takeo Fujii et al.

INVESTIGATIONAL NEW DRUGS (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Bertrand Routy et al.

SCIENCE (2018)

添加到收藏夹

Article Medicine, General & Internal

IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma

Seiji Kishi et al.

INTERNAL MEDICINE (2018)

添加到收藏夹

Letter Medicine, General & Internal

Representation of Patients With Chronic Kidney Disease in Trials of Cancer Therapy

Abhijat Kitchlu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Review Oncology

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Xiaolei Li et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

Sara Valpione et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2018)

添加到收藏夹

Article Oncology

Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report

Naoki Takahashi et al.

LUNG CANCER (2018)

添加到收藏夹

Review Oncology

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis

Romualdo Barroso-Sousa et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Surgery

Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients

Ouidad Zehou et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2018)

添加到收藏夹

Article Oncology

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

David Y. Oh et al.

CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report

Robin A. Daanen et al.

JOURNAL OF IMMUNOTHERAPY (2017)

添加到收藏夹

Article Medicine, Research & Experimental

Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma

Yuki Kobari et al.

IN VIVO (2017)

添加到收藏夹

Article Oncology

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

N. Chaput et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Review Urology & Nephrology

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Rimda Wanchoo et al.

AMERICAN JOURNAL OF NEPHROLOGY (2017)

添加到收藏夹

Article Urology & Nephrology

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

Anushree C. Shirali et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2016)

添加到收藏夹

Letter Surgery

Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection

T. Alhamad et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2016)

添加到收藏夹

Article Oncology

Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma

L. Spain et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Review Endocrinology & Metabolism

Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review

M. N. Joshi et al.

CLINICAL ENDOCRINOLOGY (2016)

添加到收藏夹

Review Immunology

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

Chrisann Kyi et al.

IMMUNOTHERAPY (2016)

添加到收藏夹

Article Urology & Nephrology

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

Frank B. Cortazar et al.

KIDNEY INTERNATIONAL (2016)

添加到收藏夹

Letter Medicine, General & Internal

Tumor Regression and Allograft Rejection after Administration of Anti-PD-1

Evan J. Lipson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Review Oncology

Parathyroid Hormone-Related Peptide-Linked Hypercalcemia in a Melanoma Patient Treated With Ipilimumab: Hormone Source and Clinical and Metabolic Correlates

Teresa Anne Mills et al.

SEMINARS IN ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Ahmad A. Tarhini et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

Ipilimumab Granulomatous Interstitial Nephritis

Bijin Thajudeen et al.

AMERICAN JOURNAL OF THERAPEUTICS (2013)

添加到收藏夹

Article Oncology

Patterns of Onset and Resolution of Immune-Related Adverse Events of Special Interest With Ipilimumab Detailed Safety Analysis From a Phase 3 Trial in Patients With Advanced Melanoma

Jeffrey S. Weber et al.

CANCER (2013)

添加到收藏夹

Review Urology & Nephrology

Chronic kidney disease following acute kidney injury-risk and outcomes

Kelvin C. W. Leung et al.

NATURE REVIEWS NEPHROLOGY (2013)

添加到收藏夹

Article Oncology

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Jeffrey S. Weber et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Urology & Nephrology

Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury

Ion D. Bucaloiu et al.

KIDNEY INTERNATIONAL (2012)

添加到收藏夹

Article Oncology

Hyponatremia associated with Ipilimumab-induced hypophysitis

Zachary R. Barnard et al.

MEDICAL ONCOLOGY (2012)

添加到收藏夹

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

添加到收藏夹

Article Immunology

The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells

Wataru Ise et al.

NATURE IMMUNOLOGY (2011)

添加到收藏夹

Article Oncology

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy

Kaan Harmankaya et al.

MEDICAL ONCOLOGY (2011)

添加到收藏夹

Review Pharmacology & Pharmacy

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Ron J. Keizer et al.

CLINICAL PHARMACOKINETICS (2010)

添加到收藏夹

Article Urology & Nephrology

Long-term Risk of Mortality and Other Adverse Outcomes After Acute Kidney Injury: A Systematic Review and Meta-analysis

Steven G. Coca et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2009)

添加到收藏夹

Letter Medicine, General & Internal

Anti-CTLA4 Antibody-Induced Lupus Nephritis.

Fouad Fadel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues

Ryogo Minamimoto et al.

ANNALS OF NUCLEAR MEDICINE (2007)

添加到收藏夹

Article Dermatology

Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent

SH Jaber et al.

ARCHIVES OF DERMATOLOGY (2006)

添加到收藏夹

Article Immunology

PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis

HL Ding et al.

CLINICAL IMMUNOLOGY (2005)

添加到收藏夹

Review Cell Biology

Receptor downregulation and multivesicular-body sorting

DJ Katzmann et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.